[Clinical effects of six-month short time biofiltration]

Area of Science:

• Nephrology and Dialysis Technology
• Biomedical Engineering
• Clinical Medicine

Context:

• Patients on conventional bicarbonate hemodialysis (CBHD) often experience endothelial stimulation and suboptimal removal of certain uremic toxins.
• Short time biofiltration (SBF) presents an alternative dialysis modality with potentially improved efficiency and reduced patient-side effects.
• Evaluating SBF requires comparison against established CBHD protocols using comprehensive clinical and biochemical markers.

Purpose:

• To assess the clinical efficacy of a six-month short time biofiltration (SBF) regimen compared to conventional bicarbonate hemodialysis (CBHD).
• To evaluate SBF's impact on plasma markers of endothelial stimulation (von Willebrand factor antigen) and oxidative stress (malondialdehyde, methylguanidine/creatinine ratio).
• To compare the removal of small molecules, including beta-2 microglobulin, and the maintenance of cardiocirculatory status between SBF and CBHD.

Summary:

• A B-A-B' study involving ten patients compared six months of SBF (A) with CBHD (B, B'), utilizing an F80 hemodiafilter.
• While SBF showed no significant differences in ultrafiltration, blood pressure, cardiac function, or most biochemical markers compared to CBHD, it led to increased blood urea nitrogen, c-PTH, and methylguanidine/creatinine ratio.
• Notably, serum magnesium and beta-2 microglobulin decreased during SBF, which was also found to be less stimulative to the endothelium and superior in beta-2 microglobulin removal than CBHD.

Impact:

• Short time biofiltration (SBF) is as effective as conventional bicarbonate hemodialysis (CBHD) in removing small molecules and maintaining cardiocirculatory stability.
• SBF demonstrates a significant advantage over CBHD in clearing beta-2 microglobulin, a marker associated with long-term dialysis complications.
• The findings suggest SBF may offer a reduced endothelial stimulation profile compared to CBHD, potentially benefiting patients with vascular complications.